Advertisement

William Howard Frishman, MD: A Conversation With the Editor

      Dr. Bill Frishman is Professor of Medicine and Pharmacology and Chairman of the Department of Medicine of New York Medical College in Valhalla, New York, and also Chief of Medicine at Westchester County Medical Center in Valhalla, which is located in the northern suburbs of New York City. He was born in the Bronx, grew up in the Bronx, and except for his 6 years in Boston, he has always lived in the Bronx. His father’s premature death convinced him that he wanted to be a physician and cardiologist and to work in his beloved Bronx. His career at Albert Einstein stretched from 1976 until 1997 and during this period he published approximately 180 original communications in medical journals; 391 monographs, reviews, and book chapters, and 14 books. His work has involved primarily evaluation of drugs to decrease myocardial ischemia, heart failure, blood pressure, and various arrhythmias. He has been involved in the evaluation of 50 drugs beginning with propranolol in 1973. Bill Frishman is a self-made man devoted to his family, community, country, and medical center. He is also a good guy with a good sense of humor and a good capacity for friendship.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      Further reading

      Best publications of WHF selected by WHF

        • Frishman W.H
        • Epstein A
        • Kulick S
        • Killip T
        Heart failure sixty-three years following traumatic arteriovenous fistula.
        Am J Cardiol. 1974; 34: 733-736
        • Frishman W
        • Weksler B
        • Christodoulou J
        • Smithen C
        • Killip T
        Reversal of abnormal platelet aggregability and change in exercise tolerance in patients with angina pectoris following oral propranolol.
        Circulation. 1974; 50: 887
        • Frishman W
        • Smithen C
        • Befler B
        • Kligfield P
        • Killip T
        Non-invasive assessment of clinical response to oral propranolol.
        Am J Cardiol. 1975; 35: 635-644
        • Frishman W
        • Christodoulou J
        • Weksler B
        • Smithen C
        • Killip T
        • Scheidt S
        Aspirin therapy in angina pectoris.
        Am Heart J. 1976; 92: 3-10
        • Frishman W.H
        • Christodoulou J
        • Weksler B
        • Smithen C
        • Killip T
        • Scheidt S
        Abrupt propranolol withdrawal in angina pectoris.
        Am Heart J. 1978; 95: 169
        • Sonnenblick E.H
        • Frishman W.H
        • LeJemtel T.H
        Dobutamine.
        N Engl J Med. 1979; 300: 17-22
        • Frishman W.H
        • Ribner H
        Anticoagulation in myocardial infarction.
        Am J Cardiol. 1979; 43: 1207
        • Frishman W.H
        • Kostis J
        • Strom J
        • Hosler M
        • Elkayam U
        • Davis R
        • Weinstein J
        • Sonnenblick E.H
        Clinical pharmacology of the new beta blocking drugs.
        Am Heart J. 1979; 98: 526-535
        • Frishman W.H
        • Factor S
        • Jordan A
        • et al.
        Right atrial myxoma.
        Circulation. 1979; 59: 1070
        • Elkayam U
        • LeJemtel T
        • Mathur M
        • Frishman W
        • Ribner H
        • Strom J
        • Sonnenblick E.H
        Prazosin therapy in congestive heart failure.
        Am J Cardiol. 1979; 441: 540-545
        • Becker R
        • Frishman W
        • Frater R.W.M
        Surgical management of mitral valve endocarditis.
        Chest. 1979; 75: 314
        • Davis R
        • Strom J
        • Frishman W
        Echographic findings of vegetations in bacterial endocarditis.
        Am J Med. 1980; 69: 57-63
        • Matsumoto M
        • Oka Y
        • Strom J
        • Frishman W
        • Kadish A
        • Becker R.M
        • Frater R.W.M
        • Sonnenblick E.H
        Application of transesophageal echocardiography to continuous intraoperative monitoring of left ventricular performance.
        Am J Cardiol. 1980; 46: 95-105
        • Strom J
        • Frishman W
        • Davis R
        • Matsumoto M
        • Becker R
        • Frater R.W.M
        Echocardiographic and surgical correlations in bacterial endocarditis.
        Circulation. 1980; 62: 1-164
        • Frishman W
        β-adrenoceptor antagonists.
        N Engl J Med. 1981; 305: 505-506
        • Frishman W
        Nadolol.
        N Engl J Med. 1981; 305: 678
        • Frishman W.H
        • Strom J
        • Kirschner M
        • Poland M
        • Klein N
        • Halprin S
        • LeJemtel T
        • Kram M
        • Sonnenblick E.H
        Labetalol therapy in patients with systemic hypertension and angina pectoris.
        Am J Cardiol. 1981; 48: 917-928
        • Klein N
        • Siskind S
        • Frishman W
        • Sonnenblick E
        • LeJemtel T
        Hemodynamic comparisons of intravenous amrinone and dobutamine in patients with severe congestive heart failure.
        Am J Cardiol. 1981; 48: 170-175
        • Fein S
        • Klein N
        • Frishman W
        Exercise testing soon after uncomplicated myocardial infarction.
        JAMA. 1981; 245: 1863
        • LeJemtel T.H
        • Keung E
        • Frishman W.H
        • Ribner H.S
        • Sonnenblick E.H
        Hemodynamic effects of captopril in patients with severe chronic heart failure.
        Am J Cardiol. 1982; 49: 1484-1488
        • Frishman W.H
        • Klein N.A
        • Strom J.A
        • Willens H
        • LeJemtel T.H
        • Jentzer J
        • Siegel L
        • Klein P
        • Kirschen N
        • Silverman R
        • Doyle R
        • Kirsten E
        • Sonnenblick E.H
        Superiority of verapamil to propranolol in stable angina pectoris.
        Circulation. 1982; 65: 51-59
        • Frishman W.H
        Antenolol and timolol.
        N Engl J Med. 1982; 306: 1456-1462
        • Packer M
        • Frishman W.H
        Verapamil therapy for stable and unstable angina pectoris.
        Am J Cardiol. 1982; 50: 881
        • Frishman W.H
        • Klein N
        • Klein P
        • Strom J.A
        • Tawil R
        • Strair R
        • Wong B
        • Roth S
        • LeJemtel T
        • Pollack S
        • Sonnenblick E.H
        Comparison of oral propranolol and verapamil for combined systemic hypertension and angina pectoris.
        Am J Cardiol. 1982; 50: 1164-1172
      1. Frishman WH, Klein N, Strom J, Cohen MN, Shamoon H, Willens H, et al. Comparative effects of abrupt withdrawal of propranolol and verapamil in angina pectoris. Am J Cardiol 1982;50:1991–1195.

        • Frishman W.H
        • Kirsten E
        • Kates R
        Clinical relevance of verapamil plasma levels in stable angina pectoris.
        Am J Cardiol. 1982; 50: 1180
        • Kostis J.B
        • Frishman W.H
        • Hosler M
        • et al.
        The treatment of angina pectoris with pindolol.
        Am Heart J. 1982; 104: 496
        • Kugler J
        • Maskin C
        • Laragh J
        • Sealy J
        • Frishman W.H
        • Sonnenblick E.H
        • LeJemtel T
        Regional and systemic metabolic effects of angiotensin converting enzyme inhibition during exercise in patients with severe heart failure.
        Circulation. 1982; 66: 1256-1261
        • Maskin C
        • Forman R
        • Frishman W
        • Sonnenblick E
        • LeJemtel T.H
        Failure of dobutamine to increase exercise capacity despite hemodynamic improvement in severe chronic heart failure.
        Am J Cardiol. 1983; 51: 177-182
        • Frishman W.H
        Multifactorial actions of β-adrenergic blocking drugs in ischemic heart disease.
        Circulation. 1983; 67: 11-18
        • Frishman W.H
        Pindolol.
        N Engl J Med. 1983; 308: 940-944
        • Michelson E.L
        • Frishman W.H
        • Lewis J.E
        • et al.
        Multicenter clinical evaluation of the long-term efficacy and safety of labetalol in the treatment of hypertension.
        Am J Med. 1983; 75: 68
        • Jacob H
        • Brandt L
        • Farkas P
        • Frishman W.H
        Beta-adrenergic blockade and the gastrointestinal system.
        Am J Med. 1983; 74: 1042-1051
        • Frishman W.H
        • Weinberg P
        • Peled H.B
        • Kimmel B
        • Charlap S
        • Beer N
        Calcium-entry blockers for the treatment of severe hypertension and hypertensive crisis.
        Am J Med. 1984; 77: 35
        • Frishman W.H
        • Furbert C.D
        • Friedewalk W.T
        β-Adrenergic blockade in survivors of acute myocardial infarction.
        N Engl J Med. 1984; 310: 830-837
        • Frishman W.H
        • Crawford M.H
        • DiBianco R
        • Farnham D.J
        • Katz R.J
        • Kostis J.B
        • Mohiuddin S.M
        • Sawin H.S
        • Thadani U
        • Zellner S
        Combination propranolol and bepridil therapy in angina pectoris.
        Am J Cardiol. 1985; 55: 43C-49C
        • Frishman W.H
        • Kirkendall W
        • McCarron D
        • et al.
        Diuretics versus calcium entry blockers in systemic hypertension.
        Am J Cardiol. 1985; 56: 92H-96H
        • Frishman W.H
        • Kimmel B
        • Charlap S
        • Saltzberg S
        • Stroh J
        • Weinberg P
        • Moniszko E
        • Wiezner J
        • Dorsa F
        • Pollack S
        • Strom J
        Twice daily administration of oral verapamil in the treatment of essential hypertension.
        Arch Intern Med. 1986; 146: 561-565
        • Robbins M.J
        • Frater R.W.M
        • Soeiro R
        • Frishman W.H
        • Strom J.A
        Influence of vegetation size on the clinical outcome of right-sided infective endocarditis.
        Am J Med. 1986; 80: 165
        • Goldberger J
        • Stroh J
        • Peled H
        • Cohen M
        • Frishman W.H
        The natural history and prognosis of acute pulmonary edema.
        Arch Intern Med. 1986; 146: 489
        • Frishman W.H
        • Zawada E.T
        • Smith L.K
        • Sowers J
        • Swartz S.L
        • Kirkendall W
        • Lunn J
        • McCarron D
        • Moser M
        • Schnaper H
        A comparative study of diltiazem and hydrochlorothiazide as initial medical therapy for mild to moderate hypertension.
        Am J Cardiol. 1987; 59: 615
        • Frishman W.H
        • Garofalo J.L
        • Rothschild A
        • Rothschild M
        • Greenberg S.M
        • Soberman J
        Multicenter comparison of the nifedipine gastrointestinal system and long-acting propranolol in patients with mild to moderate systemic hypertension receiving diuretics.
        Am J Med. 1987; 83: 15-19
        • Frishman W.H
        • Charlap S
        • Kimmel B
        • Teicher M
        • Cinnamon J
        • Allen L
        • et al.
        Diltiazem compared to nifedipine and combination treatment in patients with stable angina.
        Circulation. 1988; 77: 774-786
        • Frishman W.H
        • Charlap S
        Calcium-channel blockers for combined systemic hypertension and myocardial ischemia (abstr).
        Circulation. 1988; 75: V-154
        • Frishman W.H
        • Glasser S.P
        • Strom J.A
        • Schoenberger J
        • Liebson P
        • Poland M
        Effects of dilevalol on left ventricular mass and function in non-elderly and elderly hypertensive patients.
        Am J Cardiol. 1989; 63: 69I-74I
        • Frishman W.H
        • Flamenbaum W
        • Schoenberger J
        • Schwartz G.L
        • Vidt D.G
        • Neri G.S
        • Greenberg S
        • Lazar E
        • Godrey J.C
        • Stevenson A
        • Lamon K.D
        • Chang Y
        • Magner D.J
        Celiprolol in systemic hypertension.
        Am J Cardiol. 1989; 63: 839-842
        • Frishman W.H
        • Giles T
        • Greenberg S
        • Heiman M
        • Raffidal L
        • Soberman J
        • Laifer L
        • Nadelmann J
        • Lazar E
        • Strom J
        Sustained high-dose nitroglycerin transcutaneous patch therapy in angina pectoris.
        J Clin Pharmacol. 1989; 29: 1097-1105
        • Aronson M.K
        • Ooi W.L
        • Morgenstern P.H
        • Hafner A
        • Masur D
        • Crystal H
        • Frishman W
        • Fisher D
        • Katzman R
        Women, myocardial infarction and dementia in the very old.
        Neurology. 1990; 40: 1102-1106
        • Nadelmann J
        • Frishman W.H
        • Ooi W.L
        • Tepper D
        • Greenberg S
        • Guzik H
        • Lazar E.J
        • Heiman M
        • Aronson M
        Prevalence, incidence and prognosis of recognized and unrecognized myocardial infarction in persons aged 75 years or older.
        Am J Cardiol. 1990; 66: 533-537
        • Frishman W.H
        • Lazar E.J
        Reduction in mortality, sudden death, and nonfatal reinfarction with beta-adrenergic blockers in survivors of acute myocardial infarction.
        Am J Cardiol. 1990; 66: 66G-70G
        • Frishman W.H
        • Heiman M
        • Soberman J
        • Greenberg S
        • Eff J
        • for the Celiprolol International Angina Study Group
        Comparison of deliprolol and propranolol in stable angina pectoris.
        Am J Cardiol. 1991; 67: 665-670
        • Aronson M.K
        • Ooi W.L
        • Geva D
        • Masur D
        • Blau A
        • Frishman W.H
        Dementia.
        Arch Intern Med. 1991; 151: 989-992
        • Frishman W.H
        • Heiman M
        • for the Nisoldipine Multicenter Angina Study Group
        Usefulness of nisoldipine for stable angina pectoris.
        Am J Cardiol. 1991; 68: 1004-1009
        • The SHEP Cooperative Research Group
        Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension.
        JAMA. 1991; 265: 3255-3264
        • SOLVD Investigators
        Effects of angiotensin converting enzyme inhibition with enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure.
        N Engl J Med. 1991; 325: 293-302
        • Zimetbaum P
        • Frishman W.H
        • Ooi W.L
        • Derman M.P
        • Aronson M
        • Gidez L.I
        • Eder H.A
        Plasma lipid and lipoproteins and the incidence of cardiovascular disease in the old.
        Arterioscler Thromb. 1992; 12: 416-423
        • Guzik H
        • Ooi W.L
        • Frishman W.H
        • Greenberg S
        • Aronson M.K
        Hypertension.
        J Am Geriatr Soc. 1992; 40: 348-353
        • Frishman W.H
        • Nadelmann J
        • Ooi W.L
        • Greenberg S
        • Heiman M
        • Kahn S
        • Guzik H
        • Lazar E
        • Aronson M
        Cardiomegaly on chest x-ray: prognostic implications in a 10 year study of an old old cohort.
        Am Heart J. 1992; 124: 1026-1030
        • Frishman W.H
        Comparative efficacy and concomitant use of bepridil and beta blockers in the management of angina pectoris.
        Am J Cardiol. 1992; 69: 50D-60D
        • Gradman A.H
        • Frishman W.H
        • Kaihlanen P.M
        • Wong S.C
        • Friday K.J
        Comparison of sustained-release formulations of nicardipine and verapamil for mild to moderate systemic hypertension.
        Am J Cardiol. 1992; 70: 1571-1575
        • SOLVD Investigators
        Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduce left ventricular ejection fractions.
        N Engl J Med. 1992; 327: 685-691
        • Conigliaro J
        • Frishman W.H
        • Lazar E.J
        • Croen L
        Internal medicine housestaff and attending physician perceptions of the impact of New York State 405 regulations on working conditions and supervision of residents in two training programs.
        J Gen Med. 1993; 8: 502-507
        • Landau A
        • Frishman W.H
        • Alturk N
        • Adjei-Poku M
        • Fornasier-Bongo M
        • Furia S
        Improvement in exercise tolerance and immediate β-adrenergic blockade with intranasal propranolol in patients with angina pectoris.
        Am J Cardiol. 1993; 72: 995-998
        • Frishman W.H
        • Bryzinski B.S
        • Coulson L.R
        • DeQuattro V.L
        • Vlachakis N.D
        • Mroczek W.J
        • Dukart G
        • Alemayehu D
        • Koury K
        A multifactorial trial design to assess combination therapy in hypertension.
        Arch Intern Med. 1994; 154: 1461-1468
        • Frishman W.H
        • Brobyn W
        • Brown R.D
        • Johnson B.F
        • Reeves R.L
        • Wombolt D.G
        Amlodipine versus atenolol in essential hypertension.
        Am J Cardiol. 1994; 73: 50A-54A
        • Crystal H.A
        • Ortof E
        • Frishman W.H
        • Gruber A
        • Hershman D
        • Aronson M
        Serum vitamin B12 levels and incidence of dementia in a healthy elderly population.
        J Am Geriatr Soc. 1994; 42: 933-936
        • Hershman D.L
        • Simonoff P.A
        • Frishman W.H
        • Paston F
        • Aronson M.K
        Drug utilization in the old old, and how it relates to self-perceived health and all cause mortality.
        J Am Geriatr Soc. 1995; 43: 356-360
        • Feinfeld D.A
        • Guzik H
        • Carvounis C.P
        • Lynn R.I
        • Somer B
        • Aronson M
        • Frishman W.H
        Sequential changes in renal function tests in the old old.
        J Am Geriatr Soc. 1995; 43: 412-414
        • Frishman W
        • Pepine C.J
        • Weiss R
        • Baiker W.M
        • for the Zatebradine Study Group
        Addition of zatebradine, a direct sinus node inhibitor, provides no greater exercise tolerance benefit in patients with angina pectoris taking extended-release nifedipine.
        J Am Coll Cardiol. 1995; 26: 305-312
        • Frishman W.H
        • Ram C.V.S
        • McMahon F.G
        • Chrysant S.G
        • Graff A
        • Kupiec J.W
        • Hsu H
        • for the Benazepril/Amlodipine Study Group
        Comparison of amlodipine and benazepril monotherapy to combination therapy in patients with systemic hypertension.
        J Clin Pharmacol. 1995; 35: 1060-1066
        • Pratt C.V.M
        • McMahon R.P
        • Goldstein S
        • Pepine C.J
        • Andrews T.C
        • Dyrda I
        • Frishman W.H
        • Geller N.L
        • Hill J.A
        • Morgan N.A
        • Stone P.H
        • Knatterud G.L
        • Sopko G
        • Conti C.R
        • for the ACIP Investigators
        Comparison of subgroups assigned to medical regimens used to suppress cardiac ischemia (The Asymptomatic Cardiac Ischemia Pilot (ACIP) Study.
        Am J Cardiol. 1996; 77: 1302-1309
        • Kahn S
        • Frishman W.H
        • Weissman S
        • Ooi W.L
        • Aronson M
        Left ventricular hypertrophy on electrocardiogram: prognostic implications from a 10 year cohort study of older subjects.
        J Am Geriatr Soc. 1996; 44: 524-529
        • Stone P.H
        • Chaitman B
        • McMahon R.P
        • Andrews T.C
        • MacCallum G
        • Sharaf B
        • Frishman W
        • Deanfield J.E
        • Sopko G
        • Pratt C
        • Goldberg A.D
        • Rogerts W.J
        • Hill J
        • Proschan M
        • Pepine C.J
        • Bourassa M.G
        • Conti C.R
        • for the ACIP Investigators
        Relationship between exercise-induced and ambulatory ischemia in patients with stable coronary disease.
        Circulation. 1996; 94: 1537-1544
        • Frishman W.H
        • Heiman M
        • Karpenos A
        • Ooi W.L
        • Mitzner A
        • Goldkorn R
        • Greenberg S
        Twenty-four hour ambulatory electrocardiography in elderly subjects: prevalence of various arrhythmias and prognostic implications.
        Am Heart J. 1996; 132: 297-302
        • Bernstein J.M
        • Frishman W.H
        • Chang C.J
        Value of ECG PR and QTc interval prolongation and heart rate variability for predicting cardiovascular morbidity and mortality in the elderly.
        Cardiol in Elderly. 1997; 5: 31-41
        • Frishman W.H
        Mibefradil.
        J Cardiovasc Pharmacol Ther. 1997; 2: 321-330
        • Frishman W.H
        • Gomberg-Maitland M
        • Hirsch H
        • et al.
        Differences between male and female patients with regard to baseline demographics and clinical outcome in the Asymptomatic Cardiac Ischemia Pilot (ACIP) Trial.
        Clin Cardiol. 1998; 21: 184-190

      Books

        • Frishman W.H
        Current Cardiovascular Drugs. 2nd ed. Current Science, North American edition, Philadelphia1995
        • Goldberg D.E
        • Frishman W.H
        Beta3 Adrenergic Agonism. Futura Publishing, New York1995
        • Frishman W.H
        • Sonnenblick E.H
        Cardiovascular Pharmacotherapeutics. McGraw Hill, New York1997
      1. Frishman WH, Sonnenblick EH (eds). Cardiovascular Pharmacotherapeutics Companion Handbook. New York: McGraw Hill 1998, in press.

      2. Frishman WH (co-editor). Yearbook of Medicine 1998. St. Louis: Mosby 1998, in press.

      Monographs, Chapters in Books

        • Frishman W.H
        Clinical pharmacology of the new beta-adrenergic blocking agents.
        Am Heart J. 1979; 97: 663-670
        • Spivack C
        • Ocken S
        • Frishman W.H
        Calcium antagonists.
        Drugs. 1983; 25: 154-177
        • Frishman W.H
        • Charlap S
        Verapamil in the treatment of chronic stable angina.
        Arch Intern Med. 1983; 143: 1407
        • Michelson E.L
        • Frishman W.H
        Labetalol.
        Ann Intern Med. 1983; 99: 553
        • Frishman W.H
        • Furberg C.D
        • Friedewald W.T
        The use of β-adrenergic blocking drugs in patients with myocardial infarction.
        Curr Probl Cardiol. 1984; 9: 3-70
        • Frishman W.H
        Beta-adrenergic blocker withdrawal.
        Am J Cardiol. 1987; 59: 26F-32F
        • Maza S.R
        • Frishman W.H
        Therapeutic options to minimize free radical damage and thrombogenicity in ischemic/reperfused myocardium.
        Am Heart J. 1987; 114: 1206-1215
        • Kralstein J
        • Frishman W.H
        Malignant pericardial disease.
        Am Heart J. 1987; 113: 785
        • Schoen R.E
        • Frishman W.H
        • Shamoon H
        Hormonal and metabolic effects of calcium-channel antagonists in man.
        Am J Med. 1988; 84: 492-504
        • Hachamovitch R
        • Strom J.A
        • Sonnenblick E.H
        • Frishman W.H
        Left ventricular hypertrophy in hypertension and the effects of antihypertensive drug therapy.
        Curr Probl Cardiol. 1988; 13: 371-421
        • Frishman W.H
        • Skolnick A.E
        • Strom J.A
        Effects of calcium-entry blockade on hypertension-induced left ventricular hypertrophy.
        Circulation. 1989; 80: IV-151-IV-161
        • Skolnick A.E
        • Frishman W.H
        Calcium channel blockers in myocardial infarction.
        Arch Intern Med. 1989; 149: 1669-1677
        • Charlap S
        • Lichstein E
        • Frishman W.H
        Electromechanical disassociation.
        Am Heart J. 1989; 118: 355-360
        • Frishman W.H
        • Garofalo J.L
        • Rothschild A
        • Rothschild M
        • Greenberg S.M
        • Soberman J
        The nifedipine gastrointestinal therapeutic system in the treatment of hypertension.
        Am J Cardiol. 1989; 64: 65F-69F
        • Frishman W.H
        • Sokol S
        • Aronson M.K
        • Wassertheil-Smoller S
        • Katzman R
        Risk factors for cardiovascular and cerebrovascular diseases and dementia in the elderly (monograph).
        Curr Probl Cardiol. 1998; 23: 1-68
        • Frishman W.H
        • Charlap S
        The alpha- and beta-adrenergic blocking drugs.
        in: Parmley W.W Cardiology. Lippincott, Philadelphia1990: 1-18
        • Frishman W.H
        “Something Special”.
        Einstein Uart J Biol Med. 1990; 8: 31-33
        • Nadelmann J
        • Frishman W.H
        Clinical use of β-adrenoceptor blockade in systemic hypertension.
        Drugs. 1990; 39: 862-876
        • Zimetbaum P
        • Frishman W
        • Aronson M
        Hyperlipidemia, vascular diseases, and dementia with advancing age.
        Arch Intern Med. 1991; 151: 240-244
        • Frishman W.H
        • Lazar E.J
        • Gorodokin G
        Pharmacokinetic optimization of therapy with beta-adrenergic blocking agents.
        Clin Pharmacokin. 1991; 20: 311-318
        • Frishman W.H
        • Skolnick A.E
        • Miller K.P
        Secondary prevention post infarction.
        in: Gersh B.J Rahimtoola S.H Management of Myocardial Infarction. Elsevier Science, New York1991: 469-492
        • Dustan H.P
        • Caplan L.R
        • Curry C.L
        • DeLeon A.C
        • Douglas F.L
        • Frishman W
        • Hill M.N
        • Washington R.L
        • Steigerwalt S
        • Shulman N
        • Taubert K
        • Champagne B
        Report of the Task Force on the Availability of Cardiovascular Drugs to the Medically Indigent.
        Circulation. 1992; 85: 849-860
        • Frishman W.H
        Comparative pharmacokinetic and clinical profiles of angiotensin converting enzyme inhibitors and calcium antagonists in systemic hypertension.
        Am J Cardiol. 1992; 69: 17C-25C
        • Frishman W.H
        Tolerance, rebound and time-zero effect of nitrate therapy.
        Am J Cardiol. 1992; 70: 43G-48G
      1. Frishman WH. β-Adrenergic blockers. In: Izzo JL, Jr, Black HR, eds. Hypertension Primer of the American Heart Assn. 1993;297–300.

        • Frishman W.H
        • Sonnenblick E.H
        β-adrenergic blocking drugs and calcium blockers.
        in: Alexander R.W Schlant R.C Fuster V The Heart. 9th ed. McGraw Hill, New York1998: 1583-1618
        • Landau A.J
        • Gentilucci M
        • Cavusoglu E
        • Frishman W.H
        Calcium antagonists for the treatment of congestive heart failure.
        Coron Artery Dis. 1994; 5: 37-50
        • Kang P.M
        • Landau A.J
        • Eberhardt R.T
        • Frishman W.H
        Angiotensin II receptor antagonists.
        Am Heart J. 1994; 127: 1388-1401
        • Loskove J
        • Frishman W.H
        Nitric oxide donors in the treatment of cardiovascular and pulmonary diseases.
        Am Heart J. 1995; 129: 604-613
        • Schwartz J
        • Freeman R
        • Frishman W
        Clinical pharmacology of estrogens.
        J Clin Pharmacol. 1995; 35: 314-329
        • Frishman W.H
        • Huberfeld S
        • Okin S
        • Wang Y.-H
        • Kumar A
        • Shareef B
        Serotonin and serotonin antagonism in cardiovascular and non-cardiovascular disease.
        J Clin Pharmacol. 1995; 35: 541-572
        • Katz B
        • Rosenberg A
        • Frishman W.H
        Controlled release drug delivery systems in cardiovascular medicine.
        Am Heart J. 1995; 19: 359-368
        • Frishman W.H
        • Cavusoglu E
        β-Adrenergic blockers and their role in the therapy of arrhythmias.
        in: Podrid P.J Kowey P.R Cardiac Arrhythmias—Mechanisms, Diagnosis and Management. Williams & Wilkins, Baltimore1995: 421-433
        • Opie L.H
        • Frishman W.H
        Lipid-lowering and antiatherosclerotic drugs.
        in: Opie L.H Drugs for the Heart. 4th ed. WB Saunders, Philadelphia1995: 288-307
        • Opie L.H
        • Sonnenblick E.H
        • Frishman W.H
        • Thadani U
        β-Blocking drugs.
        in: Opie L.H Drugs for the Heart. 4th ed. WB Saunders, Philadelphia1995: 1-30
        • Opie L.H
        • Frishman W.H
        • Thadani U
        Calcium channel antagonists.
        in: Opie L.H Drugs for the Heart. 4th ed. WB Saunders, Philadelphia1995: 50-82
        • Patel R.C
        • Frishman W.H
        Aids and the Heart.
        Cardiovasc Pathol. 1995; 4: 173-183
        • Cavusoglu E
        • Frishman W.H
        Sotalol.
        Prog Cardiovasc Dis. 1995; 37: 423-440
        • Tamirisa P
        • Frishman W.H
        • Kumar A
        Endothelin and endothelin antagonism.
        Am Heart J. 1995; 130: 601-610
        • Frishman W.H
        • Burns B
        • Atac B
        • Alturk N
        • Altajar B
        • Lerrick K
        Novel antiplatelet therapies for treatment of patients with ischemic heart disease.
        Am Heart J. 1995; 130: 877-892
        • Frishman W.H
        Postinfarction survival.
        in: Fuster V Ross R Topol E.J Atherosclerosis and Coronary Artery Disease. Lippincott-Raven, Philadelphia1996: 1205-1214
        • Frishman W.H
        • Sung H.M
        • Yee H.C.M
        • Liu L.L
        • Keefe D
        • Einzig A
        • Dutcher J
        Cardiovascular toxicity with cancer chemotherapy.
        Curr Probl Cardiol. 1996; 21: 225-288
        • Frishman W.H
        • Hotchkiss H
        Selective and non-selective dopamine receptor agonists.
        Am Heart J. 1996; 132: 861-870
        • Gomberg-Maitland M
        • Frishman W.H
        Recombinant growth hormone.
        Am Heart J. 1996; 132: 1244-1262
      2. Frishman WH. Faculty practice plan governance and management. Faculty Practice Plans. Florida: Am Coll Phys Exec, 1997.

        • Landzberg B.R
        • Frishman W.H
        • Lerrick K
        Pathophysiology and pharmacological approaches for prevention of coronary artery restenosis following coronary artery balloon angioplasty and related procedures.
        Prog Cardiovasc Dis. 1997; 34: 361-398